BioGaia Sees US Probiotics Push Bear Fruit
Marketing investments, expanded distribution and new product launches all add up to a record year for BioGaia in the US.
HBW Insight - February 17, 2026

January Brings A Slew Of Price Spikes For UK Generics
The UK generics market kicked off the new year with huge triple-digit average price rises for a host of products. Market researcher WaveData reveals the details.
Generics Bulletin - February 17, 2026

Compass Shines With Second Positive Phase III Readout For COMP360 Antidepressant
The second positive Phase III result consolidates COMP360’s six-week efficacy profile, while upcoming long-term data and FDA feedback are expected to determine the regulatory pathway forward.
Scrip - February 17, 2026

Phase III Adjuvant Lung Cancer Success For Lilly’s Retevmo
The Phase III LIBRETTO-432 study in adjuvant NSCLC treatment will increase the drug’s lead in the RET fusion-targeting field.
Scrip - February 17, 2026

Medline Recalls Beds After Reports Of Injuries and Deaths Due To Fire, Entrapment
Medline Industries has recalled several adjustable hospital bed models due to electrical hazards in the wiring that may result in the beds catching fire. The company also received reports of patients being trapped in the beds.
Medtech Insight - February 17, 2026

BREAKING: Danaher Pledges To Acquire Masimo For $9.9bn, Expanding Patient Monitoring Footprint
Under the terms of the agreement, Danaher will acquire all outstanding Masimo shares for $180 per share in cash. The company plans to finance the deal through a combination of cash on hand and proceeds from debt financing.
Medtech Insight - February 17, 2026

Gotenfia Approval Sets Stage For Multi-Player Competition On EU Golimumab
European Commission authorization clears the way for regional launches, as the newly opened golimumab biosimilars segment begins to take shape.
Generics Bulletin - February 17, 2026

Stock Watch: AstraZeneca’s Fourth-Quarter Results Are Solid, But Not Vintage
AstraZeneca’s fourth quarter leaned heavily on oncology as other segments lagged and margins missed expectations. It took CSL’s far weaker results put AstraZeneca’s solid, if unexceptional, performance into clearer perspective.
Scrip - February 17, 2026

Podcast: Hansa Biopharma On Clearing The Path To Kidney Transplant
Renée Aguiar-Lucander, CEO of Hansa Biopharma, discussed the company’s leading asset, its journey toward US FDA approval and the trials and tribulations of completing a Phase III program.
In Vivo - February 17, 2026

‘It’s Time For The Biosimilar Program To Evolve‘ – Biosimilars Forum’s Reed Sees Need For Change
As the US biosimilars market sees long-desired changes in areas such as regulatory streamlining and interchangeability, Julie Reed – executive director of the Biosimilars Forum – says there are still aspects that need to evolve.
Generics Bulletin - February 17, 2026

Kidswell Partners Up To Progress Cerebral Palsy Cell Therapy In US
Japanese venture Kidswell aiming to progress pediatric cerebral palsy cell therapy in US through new operation.
Scrip - February 17, 2026